Boehringer Ingelheim

News

Boehringer has started a phase 2 trial of an oral therapy that could help people with diabetic macular oedema avoid regular injections into the eye.

News

People in England and Wales with severe skin disease GPP will soon be able to access a new therapy currently denied to patients in Scotland.

News

Data from the CONFIDENCE trial shows the value of combining Bayer's Kerendia with an SGLT2 inhibitor to treat chronic kidney disease in diabetics.

Oncology

News

Boehringer Ingelheim has started a phase 2 trial of a drug that could offer the first oral drug for geographic atrophy, a major cause of sight loss.

Market Access

At Reuters Pharma Europe, Francesco Di Marco of Boehringer Ingelheim focused on the importance of innovating together.